Recent news highlights Nu-Med Plus's patent activity and clinical trial monitoring related to nitric oxide delivery devices and treatments.

• Nu-Med Plus announced the filing of a U.S. provisional patent application for nitric oxide in aqueous solution for wound care treatment [N1].
• The company received a patent for a single-use or short-term nitric oxide delivery device [N2].
• Patent issuance was allowed for a single-use or short-term nitric oxide delivery device [N3].
• Nu-Med Plus is closely monitoring outcomes of two new human clinical trials using inhaled nitric oxide in the treatment of COVID-19 [N4].
• A patent was filed for a nitric oxide delivery device comparable to inhalers for single or short-term usage [N5].
• Nu-Med Plus presented at the 147th National Investment Banking Association Conference in New York City in November 2019 [N6].

Nu-Med's proprietary technology for on-demand generation of medical-grade nitric oxide could offer a cost-effective alternative to existing delivery systems, potentially enabling broader medical and research applications. The company's patents on delivery devices, including disposable units for pandemic use and wound care treatments, position it to address niche markets. Early prototypes for hospital, clinical, and portable delivery systems demonstrate technological progress. Monitoring of clinical trials for inhaled nitric oxide in COVID-19 treatment indicates engagement with emerging medical uses [N4].

Nu-Med faces significant challenges including suspended product development due to lack of funding, no FDA approvals for its devices, and no current revenue generation. The company operates in a competitive market dominated by established firms with FDA-approved products and greater financial and technical resources. Liquidity ratios indicate limited financial flexibility. The lengthy and costly FDA approval process presents a substantial barrier. The company's reliance on external parties for clinical studies and uncertain capital availability increase execution risk [S1].

Nu-Med's moat is based on its proprietary nitric oxide generating formulation and delivery systems designed to reduce costs and improve accessibility compared to existing products. The company holds patents for unique delivery devices, including single-use and short-term nitric oxide delivery systems. However, the moat is limited by the company's early development stage, lack of FDA approvals, and competition from well-established companies with greater resources and existing market presence.

• Funding Risk: Product development is suspended pending capital infusion, and the company currently lacks funds to pursue FDA approvals, which are necessary for commercial sales in the U.S. [S1].
• Regulatory Risk: All human medical uses require FDA approval for both the nitric oxide formulation and delivery devices. The approval process is costly, lengthy, and uncertain [S1].
• Competitive Risk: Nu-Med competes with established companies that have FDA-approved nitric oxide delivery systems and greater financial and technical resources [S1].
• Financial Risk: The company reported a net loss and has liquidity ratios indicating limited current assets relative to liabilities, which may constrain operations [S1].
• Execution Risk: Development and commercialization depend on successful refinement, testing, and regulatory approval of multiple product prototypes, which have not yet been completed [S1].

• Nu-Med Plus, Inc. is a medical device company incorporated in Utah in 2011 focused on developing technologies utilizing nitric oxide in the medical device field [S1].
• The company has developed multiple nitric oxide delivery systems including hospital, clinical, portable, disposable, and research units, but product development is currently suspended pending capital infusion [S1].
• Nu-Med's products aim to generate medical-grade nitric oxide on demand, reducing delivery costs compared to existing solutions [S1].
• The company has filed and received patents related to nitric oxide delivery devices, including a single-use or short-term delivery device and a provisional patent for nitric oxide in aqueous solution for wound care treatment [N1][N2][N3][N5].
• Nu-Med is monitoring outcomes of human clinical trials using inhaled nitric oxide for COVID-19 treatment but does not conduct its own clinical studies [N4].
• The company has not generated revenue as of the latest filings and reported a net loss of $56,182 for the fiscal year ending December 31, 2025 [S1].
• Liquidity ratios as of December 31, 2025, indicate a current ratio of 0.03 and a cash ratio of 0.01, reflecting limited current assets relative to liabilities [S1].
• Nu-Med is classified as an emerging growth company and smaller reporting company, allowing certain reduced disclosure obligations [S1].
• The company faces competition from established firms with FDA-approved nitric oxide delivery systems, including Mallinckrodt Inc., GeNO LLC, and Beyond Air [S1].
• FDA approval is required for all human medical uses of nitric oxide delivery devices, and Nu-Med currently lacks funds to pursue such approvals [S1].